Get the Stockscreener App
43.75
1.18%
0.51
After Hours:
43.75
Qiagen Nv stock is traded at $43.75, with a volume of 605.27K.
It is up +1.18% in the last 24 hours and up +5.29% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$43.24
Open:
$43.65
24h Volume:
605.27K
Relative Volume:
0.56
Market Cap:
$9.73B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
30.17
EPS:
1.45
Net Cash Flow:
$459.60M
1W Performance:
+3.94%
1M Performance:
+5.29%
6M Performance:
+0.05%
1Y Performance:
+4.52%
1-Day Range:
$43.60
$44.05
1-Week Range:
$42.04
$44.05
52-Week Range:
$39.03
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
43.75 | 9.73B | 1.97B | 92.93M | 459.60M | 1.45 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - GlobeNewswire
Citigroup Inc. Sells 1,033,291 Shares of Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN Gains FDA Clearance for Latest Respiratory Mini-Panel Test - MPO-mag
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Shareholders 23% loss in Qiagen (NYSE:QGEN) partly attributable to the company's decline in earnings over past three years - Simply Wall St
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns - MSN
Reasons to Retain QIAGEN Stock in Your Portfolio for Now - Yahoo Finance
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Qiagen (NYSE:QGEN) Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Jennison Associates LLC Raises Stock Holdings in Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN NV : Jefferies is Neutral - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Nuance Investments LLC - MarketBeat
QGEN Collaborates With McGill University Centre: Stock to Gain? - MSN
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up - MSN
Qiagen (NYSE:QGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Qiagen (NYSE:QGEN) Shares Bought by Natixis Advisors LLC - MarketBeat
180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc - MarketBeat
Victory Capital Management Inc. Has $117.33 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
What is William Blair's Estimate for Qiagen FY2024 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Pharmahungary Group participates in ambitious EU EVEREST Project - European Biotechnology News
QIAGEN collaborates with McGill University to advance microbiome research - GlobeNewswire
QIAGEN Partners with McGill to Target $1.8B Microbiome Market in Major Research Deal | QGEN Stock News - StockTitan
Zymo Research Fights Back Against Qiagen's Lawsuit, Asserts Antitrust Violations and Attempts to Stifle Innovation - Yahoo Finance
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock - Yahoo Finance
QIAGEN NV : UBS reiterates its Neutral rating - Marketscreener.com
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook - Investing.com India
Qiagen’s Financial Growth and Rising Debt in Q3 2024 - Yahoo Finance
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook By Investing.com - Investing.com Australia
Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M - MSN
Wellington Management Group LLP's Strategic Acquisition of Qiage - GuruFocus.com
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus.com
Qiagen Reports Strong Q3 2024 Growth - TipRanks
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? - Yahoo Finance
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - Marketscreener.com
Qiagen Q3 24 Earnings Conference Call At 9:30 AM ET - Nasdaq
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade - Marketscreener.com
QIAGEN NV : Receives a Buy rating from Berenberg - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Van ECK Associates Corp - MarketBeat
Qiagen N : QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full year 2024 adjusted EPS outlook - Marketscreener.com
QIAGEN NV : UBS reaffirms its Neutral rating - Marketscreener.com
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Diagnostics firm Qiagen reports rise in third-quarter revenue - Reuters
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook - The Manila Times
QIAGEN Q3 Earnings Surge: Sales Hit $502M, Boosts 2024 EPS Outlook | QGEN Stock News - StockTitan
Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
FDA clears fourth Qiagen test in 2024 - BioWorld Online
Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):